Distribution of atypical fractures and cortical stress lesions in the femur: Implications on pathophysiology

Singapore Medical Journal

Volumn 52, Issue 2, 2011, Pages 77-80

  Koh, J S B ^a   Goh, S K ^a   Png, M A ^a   Ng, A C M ^a   Howe, T S ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Advanced glycation end products; Atypical fracture; Lateral periosteal reaction; Tension failure

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; ATYPICAL FEMUR FRACTURE; BONE DENSITY; BONE RADIOGRAPHY; BONE STRESS; CLINICAL ARTICLE; FEMALE; FEMUR FRACTURE; FEMUR SHAFT; GREATER TROCHANTER; HUMAN; PATHOPHYSIOLOGY; TENSILE STRENGTH;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DISEASES, METABOLIC; FEMALE; FEMORAL FRACTURES; FEMUR; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; STRESS, MECHANICAL; TENSILE STRENGTH;

EID: 79958187572     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25:2267-94.
2. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008; 39:224-31.
3. Butler JE, Brown SL, McConnell BG. Subtrochanteric stress fractures in runners. Am J Sports Med 1982; 10:228-32.
4. Leinberry CF, McShane RB, Stewart WG Jr, Hume EL. A displaced subtrochanteric stress fracture in a young amenorrheic athlete. Am J Sports Med 1992; 20:485-7.
5. Oh I, Harris WH. Proximal strain distribution in the loaded femur. An in vitro comparison of the distributions in the intact femur and after insertion of different hip-replacement femoral components. J Bone Joint Surg Am 1978; 60:75-85.
6. Isaacs JD, Shidiak L, Harris IA, Szomor ZL. Femoral insufficiency fractures associated with prolonged bisphosphonate therapy. Clin Orthop Relat Res 2010: 468:3384-92.
7. Tang SY, Allen MR, Phipps R, Burr DB, Vashishth D. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int 2009; 20:887-94.
8. Iwata K, Allen MR, Phipps R, Burr DB Microcrack initiation occurs more easily in vertebrae from beagles treated with alendronate than with risedronate.Bone 2006; 38(Suppl):42.
9. Donnelly E, Gladnick BP, Meredith DS, Lane JM, Boskey AL Bisphosphonate treatment reduces cortical tissue heterogeneity in postmenopausal women with fractures. Transactions Orthopaedic Research Society 56th Annual Meeting. New Orleans, 2010.
10. Allen MR, Iwata K, Phipps R, Burr DB. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006; 39:872-9.
11. Koh JS, Goh SK, Png MA, Kwek EBK, Howe TS. Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? J Orthop Trauma 2010; 24:75-81.
12. Kwek EB, Koh JS, Howe TS. More on atypical fractures of the femoral diaphysis. N Engl J Med 2008; 359:316-7.
13. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007; 89:349-53.
14. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008; 22:346-50.
15. Koch JC. The laws of bone architecture. Am J Anat 1917; 21:177-298.